Fundraising FoxFGH Biotech
Houston, US · Founded 2011 · Delaware corporation
Find your way into FGH Biotech
Sign up to see every warm intro you have to FGH Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the FGH Biotech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
FGH BioTech develops small molecule drugs that regulate SREBP transcription factors and related pathways, targeting the prevention and treatment of metabolic diseases and cancer. The company's work is based on decades of research in fat and energy metabolism.
Founders & leadership
FGH Biotech was founded in 2011 by Salih J. Wakil PhD, Motonari Uesugi PhD, and Lutfi Abu-Elheiga PhD.
Board
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 of 2 rounds · 2015–2017
▶$2.1MraisedMay 2018 · 18 investors · PharmaceuticalsRule 506(b)
- Lufti Abu-ElheigaExecutive Officer
- Joe WakilExecutive Officer, Director
- Salih J WakilExecutive Officer, Director
- Adam KuspaDirector
- Offering amount
- $4M
- Amount sold
- $2.1M
- Minimum investment
- $12.5K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MofferedNov 2015 · PharmaceuticalsRule 506(b)
- Adam KuspaDirector
- Lufti Abu-ElheigaExecutive Officer
- Joe WakilExecutive Officer, Director
- Salih J WakilExecutive Officer, Director
- Offering amount
- $2.5M
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $324.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does FGH Biotech do?
- FGH BioTech develops small molecule drugs that regulate SREBP transcription factors and related pathways, targeting the prevention and treatment of metabolic diseases and cancer. The company's work is based on decades of research in fat and energy metabolism.
- Who founded FGH Biotech?
- FGH Biotech was founded by Salih J. Wakil PhD, Motonari Uesugi PhD, Lutfi Abu-Elheiga PhD in 2011.
- How much funding has FGH Biotech raised?
- FGH Biotech has disclosed $2.1M raised across 1 of its 2 known rounds.
- Where is FGH Biotech headquartered?
- FGH Biotech is headquartered in Houston, US.